Memantine Hydrochloride(meh man’ teen)
Apo-Mematine (CAN), Co-Memantine (CAN), Ebixa (CAN), Namenda, Namenda XRDNC, PMS-Memantine (CAN), ratio-Memantine (CAN), Riva-Memantine (CAN)
PREGNANCY CATEGORY B
Drug Classes
Alzheimer disease drug
N-methyl-D-aspartate (NMDA) receptor antagonist
Therapeutic Actions
Exerts a low to moderate affinity for NMDA receptor sites with no effects on GABA, dopamine, histamine, glycine, or adrenergic receptor sites; persistent activation of the CNS NMDA receptors by the excitatory amino acid glutamate has been suggested to contribute to the symptomatology of Alzheimer disease.
Indications
Treatment of moderate to severe dementia of the Alzheimer type
Unlabeled uses: Treatment of vascular dementia, treatment of ADHD, prevention of migraines, treatment of post-herpetic neuralgia
Contraindications and Cautions
Contraindicated with allergy to memantine or any component of the drug.
Use cautiously with pregnancy, lactation, renal impairment, severe hepatic impairment.
Available Forms
Tablets—5, 10 mg; ER capsulesDNC—7, 14, 21, 28 mg; oral solution—2 mg/mL
Dosages
Adults
Initially, 5 mg/day PO, increase at weekly intervals to 5 mg bid (10 mg/day), 15 mg/day (5 mg and 10 mg doses) with at least 1 week between increases; target dose is 20 mg/day (10 mg bid). Use solution-dosing device if solution is used. If using ER form: Initially, 7 mg PO once a day; may be increased by 7 mg/day after at least 1 week. Maintenance dose is 28 mg PO once daily.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
